Cargando…

The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review

There is a vital role of B cells in the pathogenesis of Systemic Lupus Erythematosus (SLE). Belimumab (Bel), an inhibitor of B cell activating factor (BAFF), and Rituximab (RTX), a monoclonal antibody targeting Cd20 antigen, have been used to manage systemic lupus. Several randomized controlled tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Abid, Naushad, Manaye, Sara, Naushad, Hamzah, Cheran, Kaaviya, Murthy, Chinmayee, Bornemann, Elisa A, Kamma, Hari Krishna, Alabbas, Mohammad, Elashahab, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360028/
https://www.ncbi.nlm.nih.gov/pubmed/37485087
http://dx.doi.org/10.7759/cureus.40719
_version_ 1785076012595281920
author Abid, Naushad
Manaye, Sara
Naushad, Hamzah
Cheran, Kaaviya
Murthy, Chinmayee
Bornemann, Elisa A
Kamma, Hari Krishna
Alabbas, Mohammad
Elashahab, Mohammed
author_facet Abid, Naushad
Manaye, Sara
Naushad, Hamzah
Cheran, Kaaviya
Murthy, Chinmayee
Bornemann, Elisa A
Kamma, Hari Krishna
Alabbas, Mohammad
Elashahab, Mohammed
author_sort Abid, Naushad
collection PubMed
description There is a vital role of B cells in the pathogenesis of Systemic Lupus Erythematosus (SLE). Belimumab (Bel), an inhibitor of B cell activating factor (BAFF), and Rituximab (RTX), a monoclonal antibody targeting Cd20 antigen, have been used to manage systemic lupus. Several randomized controlled trials (RCTs) have evaluated these two agents' clinical efficacy and safety in different manifestations of SLE. This study aims to review the randomized control trials involving these two agents systematically and to explain if any disparity is noticed in the primary and secondary outcomes between these two agents. This study is done according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. After applying the inclusion criteria and quality assessment by independent reviewers and co-authors, relevant papers were identified, and data were extracted. The results have shown that RCTs involving Belimumab achieved primary endpoints; however, targeted endpoints were not achieved in studies involving Rituximab. It is concluded that despite the conflicting results obtained in clinical trials, both are effective in systemic lupus, as indicated in real-world clinical experience. However, better-designed multicenter studies evaluating these B-cell-targeting drugs are needed.
format Online
Article
Text
id pubmed-10360028
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-103600282023-07-22 The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review Abid, Naushad Manaye, Sara Naushad, Hamzah Cheran, Kaaviya Murthy, Chinmayee Bornemann, Elisa A Kamma, Hari Krishna Alabbas, Mohammad Elashahab, Mohammed Cureus Allergy/Immunology There is a vital role of B cells in the pathogenesis of Systemic Lupus Erythematosus (SLE). Belimumab (Bel), an inhibitor of B cell activating factor (BAFF), and Rituximab (RTX), a monoclonal antibody targeting Cd20 antigen, have been used to manage systemic lupus. Several randomized controlled trials (RCTs) have evaluated these two agents' clinical efficacy and safety in different manifestations of SLE. This study aims to review the randomized control trials involving these two agents systematically and to explain if any disparity is noticed in the primary and secondary outcomes between these two agents. This study is done according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. After applying the inclusion criteria and quality assessment by independent reviewers and co-authors, relevant papers were identified, and data were extracted. The results have shown that RCTs involving Belimumab achieved primary endpoints; however, targeted endpoints were not achieved in studies involving Rituximab. It is concluded that despite the conflicting results obtained in clinical trials, both are effective in systemic lupus, as indicated in real-world clinical experience. However, better-designed multicenter studies evaluating these B-cell-targeting drugs are needed. Cureus 2023-06-21 /pmc/articles/PMC10360028/ /pubmed/37485087 http://dx.doi.org/10.7759/cureus.40719 Text en Copyright © 2023, Abid et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Allergy/Immunology
Abid, Naushad
Manaye, Sara
Naushad, Hamzah
Cheran, Kaaviya
Murthy, Chinmayee
Bornemann, Elisa A
Kamma, Hari Krishna
Alabbas, Mohammad
Elashahab, Mohammed
The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
title The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
title_full The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
title_fullStr The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
title_full_unstemmed The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
title_short The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
title_sort safety and efficacy of rituximab and belimumab in systemic lupus erythematosus: a systematic review
topic Allergy/Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360028/
https://www.ncbi.nlm.nih.gov/pubmed/37485087
http://dx.doi.org/10.7759/cureus.40719
work_keys_str_mv AT abidnaushad thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT manayesara thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT naushadhamzah thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT cherankaaviya thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT murthychinmayee thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT bornemannelisaa thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT kammaharikrishna thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT alabbasmohammad thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT elashahabmohammed thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT abidnaushad safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT manayesara safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT naushadhamzah safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT cherankaaviya safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT murthychinmayee safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT bornemannelisaa safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT kammaharikrishna safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT alabbasmohammad safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview
AT elashahabmohammed safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview